Further re Shareholder Loan

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN ARTICLE 7 OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.

UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

genedrive plc

("genedrive" or the "Company")

Further re Shareholder Loan

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 31 October 2025 in relation to a potential shareholder loan (the "Loan") from David Nugent, a significant shareholder in the Company, that heads of terms for the Loan have now been agreed between the parties.

Subject to the signing of definitive agreements it is proposed that the Loan will include the following key terms:

· An aggregate amount of £1 million which can be drawn down by the Company in two equal tranches of £500,000 with the first tranche to be available to be drawn from the time that definitive legal agreements are entered into.

· When drawn the Loan will be secured against a fixed and floating charge over all of the Company's assets including its intellectual property and patents, until repaid in full.

· The first £500,000 tranche will be provided to genedrive without any commitment fees, charges or interest whereas the second tranche, if drawn, would incur a one-off fixed charge of £50,000 which will be added to the total amount of the loan when repaid. The second tranche can be drawn post 20 February 2026.

· The Loan is for a maximum period of twelve months from the date that the Loan documentation is signed.

The entering into of the Loan will represent a related party transaction under AIM Rule 13.

Dr Gino Miele, CEO of genedrive plc, said: "With heads of terms now agreed with David we will look to rapidly progress documentation to provide the Company with the optionality of accessing this Loan. On behalf of the Board I would like to extend my thanks to David for his indicated support for the Company which would significantly improve the Company's working capital position."

Mr David Nugent, said: "I look forward to further constructive discussions with Gino and the Board and ultimately ensuring that the Company has the financial and other resources it needs to deliver for patients and shareholders."

For further details please contact:

​

About genedrive plc ( http://www.genedrive.com )

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.